Actavis could make out big time with FDA’s knock to Mallinckrodt, Kudco drugs

Eric Palmer While the industry is fixated on whether Actavis will save Allergan from a hostile takeover by Valeant or whether Pfizer might be sizing up a run at Actavis, there was a ...

Place your bets: Biotechs hustle along new drugs for blockbuster liver diseases

John Carroll Late last week investors wound up using Intercept Pharmaceuticals as a punching bag after new data on its NASH drug for fatty liver disease raised some troubling questions ...

Actavis rides success of branded drugs and M&A to positive Q3

Emily Wasserman Actavis has been inking deals with Forest Laboratories and Warner Chilcott to get its hands on the companies' suite of branded products. Now, the company is celebrating ...

Which drugs win the script popularity contest? Crestor, Synthroid and Nexium

Tracy Staton If we could see inside every medicine chest in the United States, which pill bottles or delivery devices would we see most often? Some numbers from the IMS Institute for ...

Report: Orphan drugs to nab 19% of drug sales by 2020–if payers don’t balk, that is

Carly Helfand Pharma companies have been quick to get on board with the orphan drug development trend in recent years, racing to bring pricey treatments for small patient populations ...

Merck and Roche prep breast cancer data for promising PD-1 drugs

Emily Mullin As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer ...

Take your drugs, get a prize? West and HealthPrize test new adherence plot

Carly Helfand West Pharmaceutical Services and HealthPrize Technologies are taking gamification to the next level. The companies are teaming up on a new, interactive initiative that ...

Top execs bicker over Sanofi’s plan to unload $8B portfolio of old drugs

Arlene Weintraub Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. ...

Catalyst Pharma to join parade of huge price hikes on old, cheap drugs

Tracy Staton Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand–and adding an enormous premium along the way. Once again, the cost increase ...

Big Pharma to share abandoned drugs, Actelion M&A rumors resume, Gaza war threatens IPOs

Nick Paul Taylor In this week's EuroBiotech Report, events in Gaza and Ukraine have cast a shadow over Europe, with sections of the Israeli biotech industry among the many groups ...

Cost-conscious payers are eyeing higher prices on diabetes drugs

Tracy Staton A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable ...

JAMA: Hep C drugs could add $300 to every American’s insurance premium

Tracy Staton The payer panic over the cost of Gilead Sciences' pricey-and-wildly-successful hepatitis C drug Sovaldi has been well documented. But now, one of the ...
Page 3 of 1212345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS